anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Approval from Ethical Committee of Faculty of Medicine Universitas Indonesia was acquired prior conducting the study. Subjects were given informed consent before enrolling the study. Intravenous (IV) cannula (20 G) , non-invasive blood pressure monitor, and pulse-oxymetry had been set on the subjects in endoscopic room. Vital signs were recorded. Subjects were then randomized into two groups (Ketamine:propofol ratio of 1:6 \[K16\] and ketamine:propofol ratio of 1:4 \[K14\]). K16 group's drug mixture was ketamine:propofol with ratio of 1:6, filled in 50 cc syringe, which consisted of 1 ml of ketamine (50 mg/ml), 30 ml of 1% propofol (10 mg/ml), and 19 ml of normal saline so that every ml of mixture consisted of 1 mg of ketamine and 6 mg of propofol. K14 group's drug mixture was ketamine:propofol with ratio of 1:4, filled in 50 cc syringe, which consisted of 1 ml of ketamine (50 mg/ml), 20 ml of 1% propofol (10 mg/ml), and 29 ml of normal saline so that every ml of mixture consisted of 1 mg of ketamine and 4 mg of propofol. Patient then was given initial bolus dose of 1 mg/kg body weight (BW) (based on propofol dose) and continued with maintenance dose of propofol (50 mcg/kg BW/minute, based on propofol dose). Maintenance dose could be increased by 10 mcg/kg BW/ minute if the subject still gave response to surgical stimulation or decreased by 10 mcg/kg BW/minute if hypotension occured. Onset of the drug, vital signs every 5 minutes, hypotension and desaturation events were recorded. If there were signs of pain such as tachycardia or hypertension, an additional dose of 25 mcg of fentanyl intravenous was given and recorded. After the endoscopic retrograde cholangiopancreatography (ERCP) finished, drugs were stopped and the total doses of propofol, drug administration speed, total dose of fentanyl used, and recovery time were recorded. Subjects were moved to the recovery room and observed for side effects event. Subjects were moved to the ward after aldrete score of 9-10.
BACKGROUND AND AIMS: Epidemiological evidence on the associations between female reproductive features and nonalcoholic fatty liver disease (NAFLD) is conflicting. To explore their causalities, we conducted a Mendelian randomization (MR) study.
METHODS: Summary-level data were obtained, and univariable MR was performed to explore the causalities between female reproductive features and NAFLD. And we performed multivariable MR and MR mediation analysis to explore the mediation effects of educational attainment (EA) and body mass index (BMI) for these associations. Sensitivity analyses were performed to evaluate pleiotropy and heterogeneity.
RESULTS: There were causal effects of age at menarche (AAMA) (odds ratio [OR]: 0.817, 95% confidence interval [CI]: 0.736-0.907, per year-increase), age at first birth (AFB) (OR: 0.851, 95%CI: 0.791-0.926, per year-increase) and age at first sexual intercourse (AFS) (OR: 0.676, 95%CI: 0.511-0.896, per standard deviation-increase) on NAFLD risk. Besides, the causal effects were also observed on NAFLD phenotypes including liver fat content (LFC) and alanine aminotransferase (ALT). Further mediation analysis showed that BMI mediated partial proportion of effects of AAMA and AFS on NAFLD/ALT, AFB on NAFLD/LFC/ALT, while EA mediated partial proportion of effects of AFB on NAFLD/LFC/ALT, and AFS on NAFLD/ALT.
CONCLUSIONS: This study provided convincing evidence that early AAMA, AFB, and AFS were risk factors for NAFLD. Reproductive health education, obesity management, and education spread might be the beneficial strategies for NAFLD prevention.
The present invention relates to an effervescent toothpaste in a bead form, and a container suitable therefor. More specifically, the toothpaste is prepared to a solid toothpaste having a bead form, which is easily portable using a carton or a receptacle, and the toothpaste is added with effervescent components, which enhances the effect of portability. To this end, the toothpaste is produced into a solid type bead, which enables to regulate a dose of toothpaste using the unit number of beads, thus preventing a mistake in regulating a dose. The toothpaste has effervescent characteristics, providing greater effects with a small dose. Accordingly, it is possible to save the toothpaste and contributes to the protection of environment. In addition, the toothpaste having effervescent characteristics of the present invention helps children to enjoy brushing teeth.
Group 1 will receive EEG-RTNF training from the PCC. They will attend an 8 week MBSR class. This feedback will occur at weeks 3, 4, 6 and 7.
PROBLEM TO BE SOLVED: To obtain the subject compound excellent in storage stability, easy in handleability, and useful as a medicine for treating or preventing diseases caused by the abnormal absorption, transport or metabolism of calcium. SOLUTION: This vitamin D derivative of crystal form is represented by formula I. The derivative can be obtained by applying a crystallization treatment to a vitamin D derivative of amorphous form represented by formula II in an organic solvent containing water. For example, 10mg of the vitamin D derivative of amorphous form represented by formula II is dissolved in 0.2ml of diethyl ether, and the obtained solution is mixed with 1.35ml of toluene and subsequently stirred, until giving a homogeneous solution. The homogeneous solution is concentrated under vacuum, until being reduced to a half volume of the solution, mixed with three drops (approximately 100mg) of purified water and further stirred at room temperature for >=15hr. The treated solution is cooled to approximately 5 deg.C, and the deposited crystals are filtered off to obtain 7mg of the vitamin D derivative or crystal form.
A system, apparatus and method for configuring notifications pursuant to a medical regimen for a patient. A communications interface receives patient data and patient feedback data associated with the patient and system patient data associated with other patients may be stored. A data model is processed for the medical regimen to calculate a baseline notification schedule based on the patient data, wherein the baseline notification schedule includes content and notification frequency for individual notifications. The patient data is processed to determine word vectors and embedded vectors. Statistical/predictive processing is executed on the processed patient feedback data to determine a patient characteristic. As a result of the statistical/predictive processing, the baseline notification schedule is modified to form a modified schedule for transmission in the system.
PURPOSE: To obtain an antioxidant, consisting essentially of a specific thianthrene-2,3,7,8-tetrols, capable of manifesting excellent antioxidizing activities without any skin irritancy or sensitizing properties, excellent in preservation stability and useful as a cosmetic or a skin preparation for external use, etc., for preventing and reducing the skin senescence. CONSTITUTION: This antioxidant consists essentially of compounds represented by the formula (R1 and R2 are each H, an alkyl, an alkenyl or an aryl) (e.g. thianthrene-2,3,7,8-tetrol). When the compounds which are antioxidant components are blended with a base for a preparation for external use such as a cream or an ointment and used, an extremely trace amount of 1-500μg compounds, represented by the formula, based on 100g product and blended therein is effective.  A skin cream containing the antioxidant blended therein is obtained by mixing and dissolving, e.g. an oily phase ingredient for the cream with the antioxidant, heating the resultant mixture at 75 deg.C, adding the prepared solution to another aqueous solution of a water- soluble ingredient for the cream heated at 75 deg.C, preemulsifying the mixture, uniformly emulsifying the preemulsion with a homomixer, cooling the prepared emulsion and adding a perfume thereto at 50 deg.C.
The present invention provides a recombinant fowlpox virus designated S-FPV-097. The present invention also provides a vaccine which comprises an effective immunizing amount of the recombinant fowlpox virus designated S-FPV-097 and a suitable carrier. The present invention further provides a method of immunizing an animal against disease caused by fowlpox virus, Newcastle disease virus, and infectious laryngotracheitis virus which comprises administering to an animal an effective immunizing dose of the vaccine of the present invention and a suitable carrier. The present invention further provides recombinant fowlpox viruses designated S-FPV-095, S-FPV-074, S-FPV-081, and S-FPV-085. The present invention further provides a vaccine which comprises an effective immunizing amount of the fowlpox viruses of the present invention and a suitable carrier. The present invention further provides a method of immunizing an animal against disease caused by fowlpox virus, Newcastle disease virus, infectious laryngotracheitis virus or Marek's disease virus which comprises administering to an animal an effective immunizing dose of the vaccines of the present invention.
Clinical surgery can lead to severe neuroinflammation and cognitive dysfunctions. It has been reported that astrocytes mediate memory formation and postoperative cognitive dysfunction (POCD), however, the thalamic mechanism of astrocytes in mediating POCD remains unknown. Here, we report that reactive astrocytes in zona incerta (ZI) mediate surgery-induced recognition memory impairment in male mice. Immunostaining results showed that astrocytes are activated with GABA transporter-3 (GAT-3) being down-expressed, and neurons were suppressed in the ZI. Besides, our work revealed that reactive astrocytes caused increased tonic current in ZI neurons. Up-regulating the expression of GAT-3 in astrocytes ameliorates surgery-induced recognition memory impairment. Together, our work demonstrates that the reactive astrocytes in the ZI play a crucial role in surgery-induced memory impairment, which provides a new target for the treatment of surgery-induced neural dysfunctions.
Mitochondrial metabolism has been shown to play a key role in immune cell survival and function, but mitochondrial creatine kinase 2 (CKMT2) has been relatively little studied about tumor immunity. We aimed to explore the prognostic value of CKMT2 in 33 cancer types and investigate its potential immune function. We used a range of bioinformatics approaches to explore the potential carcinogenic role of CKMT2 in multiple cancers. CKMT2 was lowly expressed in 14 tumor tissues and highly expressed in 4 tumor tissues. Immunohistochemical assays showed overexpression of CKMT2 in colon cancer and rectal cancer. CKMT2 overexpression was positively correlated with the prognosis of lung adenocarcinoma and prostate cancer. CKMT2 overexpression is mainly enriched in the adaptive immune system and immune regulatory pathways of immunoglobulins. Seven cancers were positively correlated with low CKMT2 expression in tumor microenvironment analysis. Among the five cancers, low expression of CKMT2 resulted in better immunotherapy treatment outcomes. There was a strong correlation between CKMT2 and most immune-related genes in specific cancer types. CKMT2 plays an important role in tumorigenesis and cancer immunity and can be used as a prognostic biomarker and potential target for cancer immunotherapy.
Families will be randomized to a 4-week baseline period before being administered the P-Mobile app based intervention. All families will receive the same P-Mobile intervention following the baseline period. The intervention will consist of 10 lessons delivered over 12 weeks designed to increase physical activity in children. The lessons will be delivered weekly and are the same ones utilized in the P-Mobile pilot study. The parents will also receive notifications designed to prompt physical activity, motivate, and remind parents of lesson content.
Each subject will receive a dose of a placebo (150 ml of no-sugar cranberry juice) to drink. This same dose will be delivered in two separate sessions, occurring within weeks.
The COPD questionnaire was conducted to collect the data of lung function, echocardiography and blood gas analysis, and the pulmonary vessels of HRCT were determined. Blood samples were collected for H2S-related indicators detection.
This is a single-center, randomized, double-blind trial comparing combined rosiglitazone/metformin (Avandametä) to placebo in subjects with normal or intermediate fasting glucose (IFG) and stable coronary artery disease.Subjects meeting entry criteria will be randomized in a 1:1 ratio to receive either placebo or combined rosiglitazone/metformin (Avandametä) 4/1000 mg. Laboratory specimens including high sensitivity C-reactive protein (hs-CRP), glucose, HgbA1C, complete lipid profile, will be obtained after a 10 hour fast as specified by study visits. Subjects will return for repeat study visits at 2, 4, 6 and 8 months for repeat laboratory evaluations, including safety labs consisting of serum creatinine, liver enzymes, and a CBC. Additionally, subjects will have IL-6 and TNF-a measured for research purposes at baseline and subsequent follow-up visits. All subjects will be followed for a minimum of 8 months. This pilot study proposes to evaluate the effect of placebo, or combined rosiglitazone/metformin onsurrogate blood markers of atherosclerosis activity among non-diabetic and pre-diabetic patients with known stable coronary syndromes.
Risk Summary

Carmustine for Injection can cause fetal harm when administered to a pregnant woman based on the mechanism of action [see Clinical Pharmacology (12.1)] and findings in animals [see Data]. Limited available data with Carmustine for Injection use in pregnant women are insufficient to inform a drug-associated risk of major birth defects and miscarriage. Carmustine was embryotoxic in rats and rabbits and teratogenic in rats (thoracoabdominal closure, neural tube, and eye defects and malformations of the skeletal system of the fetus) when given in doses lower than the maximum cumulative human dose based on body surface area. Consider the benefits and risks of Carmustine for Injection for the mother and possible risks to the fetus when prescribing Carmustine for Injection to a pregnant woman. 

Adverse outcomes in pregnancy occur regardless of the health of the mother or the use of medications. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

Data

Animal Data

Intraperitoneal (IP) administration of carmustine to pregnant rats 14 days prior to mating and during the period of organogenesis at cumulative doses ≥ 26 mg/kg (158 mg/ m2), approximately 0.1 times the maximum cumulative human dose of 1400 mg/m2, resulted in pre-implantation loss, increased resorptions (including completely resorbed litters), and reduced the number of live births in the presence of maternal toxicity.

Carmustine administered IP to pregnant rats during the period of organogenesis at cumulative doses ≥ 4 mg/kg (24 mg/m2), approximately 0.02 times the maximum cumulative human dose based on a mg/m2 basis, resulted in reduced fetal weight and various malformations, which included thoracoabdominal closure defects, neural tube defects, and eye defects, including microphthalmia/anophthalmia, and skeletal anomalies in the skull, sternebra, vertebrae and ribs, and reduced skeletal ossification) in the presence of maternal toxicity. Embryo-fetal death was observed at cumulative doses ≥ 8 mg/kg (48 mg/m2), approximately 0.03 times the maximum cumulative human dose on a mg/ m2 basis. Intravenous (IV) administration of carmustine to rats at a cumulative dose of 50 mg/kg (300 mg/m2), approximately 0.2 times the maximum cumulative human dose on a mg/m2 basis, during the last quarter of pregnancy resulted in the death of offspring within 4 months. Carmustine administered IV to rabbits during the period of organogenesis resulted in spontaneous abortions in mothers and growth defects in the fetus, mainly at cumulative doses ≥ 13 mg/kg (156 mg/ m2), approximately 0.1 times the maximum cumulative human dose on a mg/ m2 basis.
During a 5-week intervention, we examine the patients' balance, postural control, quality of life and mobility. Thereafter, the group does not move only in everyday life.
The present invention provides a phenasteroid gel preparation mainly comprising phenasteroamine, phosphatide, low molecular weight alcohol, glycerine, carbomer, an antioxidant, triethanolamine and solvent. A new transdermal medicine supply carrier of alcohol plastid is used by the phenasteroid gel preparation. The transdermal transportation of the phenasteroamine is improved to achieve the purposes of increasing medicament targeting tropism, extending medicament action time and keeping stable blood medicament concentration, and thus, the curative effect of the medicament is enhanced. The preparation has the advantages of simple preparation process, high encapsulation efficiency, good stable performance and small side effect. The phenasteroid gel preparation can be compatible with various medicament components. When the phenasteroid gel preparation is used for transdermal approach administration, the transdermal transportation of the medicament can be improved, and the curative effect of the medicament can be enhanced.
Outpatients with mild to moderate COVID-19 symptoms and a confirmed SARS-CoV-2 infection were enrolled. These patients were randomly assigned to receive either IMMUNEPOTENT-CRP (I-CRP) or a placebo over a 14-day period. The study was double-blind, meaning neither the patients nor the researchers knew who was receiving I-CRP or placebo, ensuring unbiased results. The main objective of the study was to measure changes in the levels of specific cytokines and chemokines in the blood-IL-1β, IL-6, IL-10, TNF-α, IFN-α, IFN-γ, and IL-8-which are key players in the inflammatory response linked to severe COVID-19 cases. High levels of these molecules are associated with worse outcomes and more severe symptoms. Additionally, other markers of inflammation and immune system activity, such as lactate dehydrogenase (LDH), high-sensitivity C-reactive protein (hs-CRP), ferritin, and D-dimer, were measured, as these are commonly used to assess the severity of inflammation and risk of complications in COVID-19 patients.

Throughout the study, outpatients were regularly monitored for symptoms, and their vital signs-such as oxygen levels and body temperature-were checked during home visits. Blood samples were collected at different intervals to measure cytokine levels and the other included inflammatory markers. Patients were also tested four times for the presence of the virus to determine their infection status during the follow-up period.
This is a single-blinded 2-arm RCT. A total of 168 parent-child dyads will be recruited consecutively from the scoliosis clinic in the Duchess of Kent Children's Hospital (DKCH). Eligible parents with the children will complete the baseline questionnaires and be randomized to either ACT or control group. Parents in the ACT group will be invited to join a 30-minute small private online course (SPOC) related to AIS. Parents in the ACT group will receive five weekly online ACT group-training sessions through Zoom. The controls will receive five weekly interactive online lectures/meetings through Zoom that will cover detailed topics related to AIS information and management. A research assistant, blinded to the group allocation, will use phone calls and emails to remind all participating parents and children to complete a set of online questionnaires identical to the baseline questionnaires at 5-, 12-, and 24-week follow-ups.
OBJECTIVE: Obesity is characterized by excessive accumulation of white adipose tissue (WAT). Conversely, brown adipose tissue is protective against obesity. We recently reported liraglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), could inhibit high-fat-diet-induced obesity by browning of WAT. However, the molecular mechanism involved is not well defined. Hence, we aimed to explore whether GLP-1RA could promote brown remodeling in WAT by regulating miRNAs.
METHODS: After the obesity model was successfully constructed, C57BL/6J mice were treated with liraglutide (200 μg/kg/d) or equivoluminal saline subcutaneously for 12 weeks. Then, the deposition of abdominal fat was measured by CT scanning. At the end of the treatments, glucose and insulin tolerance in mice were assessed. Serum lipid levels were monitored and epididymal WAT (eWAT) were collected for analysis. Quantitative real-time PCR and western blot analyses were conducted to evaluate the expression of genes and miRNAs associated with white fat browning.
RESULTS: Liraglutide significantly reduced body weight and visceral fat mass. Levels of lipid profile were also improved. Liraglutide upregulated the expression of browning-related genes in eWAT. Meanwhile, the expression level of miRNAs (miR-196a and miR-378a) positively associated with the browning of WAT were increased, while the expression of miR-155, miR-199a, and miR-382 negatively related with browning of WAT were decreased.
CONCLUSION: Our findings suggest that liraglutide could promote brown remodeling of visceral WAT by bi-regulating miRNAs; this might be one of the mechanisms underlying its effect on weight loss.
The utility model relates to a skin-healing plaster. A main body is a transparent film (2) for medical use, and a pressure sensitive adhesive for medical use is coated on one side of the film (2). A lining layer (1) is coated on the pressure sensitive adhesive, and the other side of the thin film (2) is coated with a protective layer (3). The middle position of which (3) is provided with an annular press mark (4), and a communicated press mark (5) is arranged between the annular press mark (4) and an outer edge. The utility model is characterized in that both ends of the lining layer (1) are respectively provided with press marks (6, 7). The utility model has the advantages of convenient and sanitary operation, safety for sticking wounds, comfort and nature and is also convenient for people to observe the conditions of the wounds, and the utility model can be widely used for protecting the wounds and fixing venular injecting conduit in clinic.
Participants receive up to 8 weekly (early phase) or 4 bi-weekly (later phase) whole-body hyperthermia (WBH) sessions and 8 weekly cognitive behavioral therapy (CBT) sessions. Each WBH session (including preparation and cool down) is up to approximately 3.5-4 hours, and each CBT session is approximately 50 minutes.